Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II pilot study of AmBisome 2 mg/kg/day for candidemia and invasive candidiasis in nonneutropenic ICU patients
2007-000607-15Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Oct 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of amphotericin b in candidemia, invasive candidiasis and candidiasis, sponsored by Gilead Sciences. Primary endpoint: Success at end of therapy. Started Oct 2007; status: completed.
02
Drugs
amphotericin b
03
Conditions
candidemiainvasive candidiasiscandidiasis
Beyond the preview
Go deeper on 2007-000607-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000607-15.